HK1209431A1 - 艾杜糖- -硫酸酯酶的純化 - Google Patents

艾杜糖- -硫酸酯酶的純化

Info

Publication number
HK1209431A1
HK1209431A1 HK15110042.0A HK15110042A HK1209431A1 HK 1209431 A1 HK1209431 A1 HK 1209431A1 HK 15110042 A HK15110042 A HK 15110042A HK 1209431 A1 HK1209431 A1 HK 1209431A1
Authority
HK
Hong Kong
Prior art keywords
iduronate
sulfatase
purification
Prior art date
Application number
HK15110042.0A
Other languages
English (en)
Inventor
‧尼科爾斯
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209431(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of HK1209431A1 publication Critical patent/HK1209431A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK15110042.0A 2012-06-29 2015-10-14 艾杜糖- -硫酸酯酶的純化 HK1209431A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
HK1209431A1 true HK1209431A1 (zh) 2016-04-01

Family

ID=49778401

Family Applications (4)

Application Number Title Priority Date Filing Date
HK15110042.0A HK1209431A1 (zh) 2012-06-29 2015-10-14 艾杜糖- -硫酸酯酶的純化
HK15110643.3A HK1209767A1 (zh) 2012-06-29 2015-10-28 艾杜糖- -硫酸酯酶的純化
HK18108734.4A HK1249027A1 (zh) 2012-06-29 2018-07-05 艾杜糖-2-硫酸酯酶的純化
HK18108732.6A HK1249026A1 (zh) 2012-06-29 2018-07-05 艾杜糖-2-硫酸酯酶的純化

Family Applications After (3)

Application Number Title Priority Date Filing Date
HK15110643.3A HK1209767A1 (zh) 2012-06-29 2015-10-28 艾杜糖- -硫酸酯酶的純化
HK18108734.4A HK1249027A1 (zh) 2012-06-29 2018-07-05 艾杜糖-2-硫酸酯酶的純化
HK18108732.6A HK1249026A1 (zh) 2012-06-29 2018-07-05 艾杜糖-2-硫酸酯酶的純化

Country Status (38)

Country Link
US (6) US9051556B2 (zh)
EP (2) EP2867245B1 (zh)
JP (4) JP6171007B2 (zh)
KR (5) KR101380740B1 (zh)
CN (3) CN104583225A (zh)
AR (1) AR091647A1 (zh)
AU (3) AU2013282395C1 (zh)
BR (1) BR112014032567B1 (zh)
CA (2) CA3008945A1 (zh)
CL (1) CL2014003567A1 (zh)
CO (1) CO7240396A2 (zh)
CR (1) CR20140588A (zh)
CY (1) CY1121519T1 (zh)
DK (1) DK2867245T3 (zh)
DO (1) DOP2014000294A (zh)
EA (2) EA202090044A1 (zh)
ES (1) ES2689468T3 (zh)
GT (1) GT201400303A (zh)
HK (4) HK1209431A1 (zh)
HR (1) HRP20181897T1 (zh)
HU (1) HUE040769T2 (zh)
IL (4) IL236315A (zh)
LT (1) LT2867245T (zh)
MX (3) MX336715B (zh)
MY (3) MY157087A (zh)
NZ (3) NZ703093A (zh)
PE (1) PE20150720A1 (zh)
PH (3) PH12014502871A1 (zh)
PL (1) PL2867245T3 (zh)
PT (1) PT2867245T (zh)
RS (1) RS58005B1 (zh)
SG (2) SG10201703489VA (zh)
SI (1) SI2867245T1 (zh)
TR (1) TR201815811T4 (zh)
TW (2) TWI587869B (zh)
UA (1) UA121959C2 (zh)
WO (1) WO2014005014A2 (zh)
ZA (2) ZA201409397B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5901877B2 (ja) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR102318480B1 (ko) 2016-08-25 2021-10-28 제이씨알 파마 가부시키가이샤 항체 융합 단백질의 제조 방법
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 酵素補充療法用酵素を含む融合タンパク質
US20220002688A1 (en) * 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
JP2023546682A (ja) * 2020-10-23 2023-11-07 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造中に総シアル酸含量（ｔｓａｃ）を制御する方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
WO2000065070A2 (en) 1999-04-26 2000-11-02 Genentech, Inc. Cell culture process for glycoproteins
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
WO2001060991A2 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
JP4319979B2 (ja) 2002-04-26 2009-08-26 ジェネンテック・インコーポレーテッド タンパク質の非アフィニティ精製
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
TWI312368B (en) 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
EP2325301B1 (en) 2003-02-11 2015-09-02 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
CA2554883C (en) 2004-01-30 2013-10-01 Zymenex A/S Production and purification of recombinant arylsulfatase a
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
PT1885753E (pt) 2005-06-03 2011-10-06 Ares Trading Sa Produção de proteína recombinante de ligação a il-18
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
LT2245145T (lt) * 2008-01-18 2017-04-10 Biomarin Pharmaceutical Inc. Aktyvių gausiai fosforilintų žmogaus lizosominės sulfatazės fermentų gamyba ir jų panaudojimas
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
MX2013000324A (es) * 2010-06-25 2013-02-01 Shire Human Genetic Therapies Tratamiento del sindrome de sanfilippo tipo b.
WO2011163649A2 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc Methods and compositions for cns delivery of iduronate-2-sulfatase
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
JP5865839B2 (ja) * 2010-09-28 2016-02-17 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
US11530393B2 (en) 2022-12-20
ZA201803289B (en) 2021-04-28
EP3441398A1 (en) 2019-02-13
JP2016119911A (ja) 2016-07-07
AR091647A1 (es) 2015-02-18
TW201703794A (zh) 2017-02-01
LT2867245T (lt) 2018-11-12
CL2014003567A1 (es) 2015-04-24
PL2867245T3 (pl) 2019-02-28
MY180287A (en) 2020-11-27
ES2689468T3 (es) 2018-11-14
TWI587869B (zh) 2017-06-21
PH12020500027A1 (en) 2021-03-15
CA2877517A1 (en) 2014-01-03
AU2013282395B2 (en) 2015-12-03
CN104583225A (zh) 2015-04-29
WO2014005014A2 (en) 2014-01-03
CA2877517C (en) 2018-07-31
RS58005B1 (sr) 2019-02-28
EP2867245B1 (en) 2018-09-12
US20150313972A1 (en) 2015-11-05
EP2867245A2 (en) 2015-05-06
TWI553120B (zh) 2016-10-11
US20210317426A1 (en) 2021-10-14
HUE040769T2 (hu) 2019-03-28
KR20140004603A (ko) 2014-01-13
AU2018200230A1 (en) 2018-02-01
PT2867245T (pt) 2018-11-26
EP2867245A4 (en) 2016-03-09
CY1121519T1 (el) 2020-05-29
AU2016200469B2 (en) 2017-10-12
WO2014005014A3 (en) 2014-02-27
HK1249027A1 (zh) 2018-10-26
DK2867245T3 (en) 2018-11-26
HK1209767A1 (zh) 2016-04-08
US20190359958A1 (en) 2019-11-28
SG11201408761VA (en) 2015-01-29
US20240043817A1 (en) 2024-02-08
US10344270B2 (en) 2019-07-09
MY157087A (en) 2016-04-19
TW201410868A (zh) 2014-03-16
ZA201409397B (en) 2019-10-30
PH12014502871B1 (en) 2015-02-23
AU2016200469A1 (en) 2016-02-18
BR112014032567A2 (pt) 2017-08-01
JP2018121645A (ja) 2018-08-09
CO7240396A2 (es) 2015-04-17
AU2013282395A1 (en) 2015-01-29
IL248727A0 (en) 2017-01-31
GT201400303A (es) 2017-08-31
IL236315A0 (en) 2015-02-26
US9051556B2 (en) 2015-06-09
KR20220002227A (ko) 2022-01-06
PH12015502408A1 (en) 2018-03-26
UA121959C2 (uk) 2020-08-25
CA3008945A1 (en) 2014-01-03
MX336715B (es) 2016-01-28
EA201492177A1 (ru) 2015-06-30
US9492511B2 (en) 2016-11-15
DOP2014000294A (es) 2015-03-15
US20170073652A1 (en) 2017-03-16
MX366906B (es) 2019-07-30
AU2018200230B2 (en) 2020-01-02
SG10201703489VA (en) 2017-05-30
KR101380740B1 (ko) 2014-04-11
NZ733366A (en) 2019-12-20
JP6505629B2 (ja) 2019-04-24
MY192068A (en) 2022-07-25
KR20200143339A (ko) 2020-12-23
JP2020105209A (ja) 2020-07-09
BR112014032567B1 (pt) 2022-09-13
KR20190064542A (ko) 2019-06-10
IL287057A (en) 2021-12-01
MX2015000190A (es) 2015-04-08
CR20140588A (es) 2015-04-06
IL261264B (en) 2021-10-31
SI2867245T1 (sl) 2018-12-31
NZ743910A (en) 2019-12-20
PH12015502408B1 (en) 2018-03-26
CN107596357A (zh) 2018-01-19
IL261264A (en) 2018-10-31
US20140004096A1 (en) 2014-01-02
PE20150720A1 (es) 2015-05-16
CN107596358A (zh) 2018-01-19
MX2019008914A (es) 2019-09-26
EA202090044A1 (ru) 2020-07-31
KR20140002451A (ko) 2014-01-08
HK1249026A1 (zh) 2018-10-26
TR201815811T4 (tr) 2018-11-21
JP2015523072A (ja) 2015-08-13
AU2013282395C1 (en) 2016-03-24
IL236315A (en) 2016-11-30
PH12014502871A1 (en) 2015-02-23
NZ703093A (en) 2017-08-25
HRP20181897T1 (hr) 2019-01-11
EA034549B1 (ru) 2020-02-19
JP6171007B2 (ja) 2017-07-26

Similar Documents

Publication Publication Date Title
IL287057A (en) Purified iduronate-2-sulfatase
SG11201502555QA (en) Purification system
ZA201406082B (en) Use of ccr3-inhibitors
EP2826473A4 (en) NEW USE OF PATCHOULOL
SG11201403891SA (en) Purification of flaviviruses
IL263162B (en) Purification of cystathionine beta-synthase
EP2800747A4 (en) POLYMORPHY OF PERAMPANEL
IL236312A0 (en) Preparation of 18f-flucyclobin
EP2881113A4 (en) NEW APPLICATION OF POGOSTONE
SG11201406800UA (en) Purification of air
GB201209082D0 (en) Purification method
EP2892529A4 (en) USES OF (-) - PERHEXILINE
HUE039458T2 (hu) Röntgen kontrasztanyagok tisztítása
IL233446A0 (en) Polymorphic forms of paramphenel
TWM433525U (en) Structure of calorifier
EP2814499A4 (en) PURIFICATION PROCESS
GB201204173D0 (en) Water purification
GB201203494D0 (en) Hydrophobin purification